Palisade Bio, Inc. PALI
We take great care to ensure that the data presented and summarized in this overview for PALISADE BIO, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PALI
Top Purchases
Top Sells
About PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Insider Transactions at PALI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2024
|
Donald Allen Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
388
+34.77%
|
-
|
|
Nov 21
2024
|
Binxian Wei Director |
BUY
Exercise of conversion of derivative security
|
Direct |
388
+31.21%
|
-
|
|
Jun 11
2024
|
Donald Allen Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
340
+50.0%
|
-
|
|
Jun 11
2024
|
Binxian Wei Director |
BUY
Exercise of conversion of derivative security
|
Direct |
465
+49.89%
|
-
|
|
May 28
2024
|
John David Finley CEO, CFO, Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,033
-5.46%
|
$8,132
$4.76 P/Share
|
|
May 28
2024
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,068
+15.81%
|
-
|
|
May 28
2024
|
Mitchell Lawrence Jones Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,271
-16.7%
|
$5,084
$4.76 P/Share
|
|
May 28
2024
|
Mitchell Lawrence Jones Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,290
+34.95%
|
-
|
|
May 28
2024
|
Donald Allen Williams Director |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$4,000
$4.86 P/Share
|
|
May 24
2024
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
1,000
+10.6%
|
$4,000
$4.81 P/Share
|
|
May 20
2024
|
John David Finley CEO, CFO, Director |
BUY
Grant, award, or other acquisition
|
Direct |
666
+8.22%
|
$2,664
$4.97 P/Share
|
|
May 06
2024
|
John David Finley CEO, CFO, Director |
SELL
Payment of exercise price or tax liability
|
Direct |
128
-0.95%
|
$1,024
$8.46 P/Share
|
|
May 06
2024
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+3.17%
|
-
|
|
May 06
2024
|
Mitchell Lawrence Jones Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
137
-8.2%
|
$1,096
$8.46 P/Share
|
|
May 06
2024
|
Mitchell Lawrence Jones Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
460
+21.12%
|
-
|
|
Mar 11
2024
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,558
+5.43%
|
-
|
|
Feb 09
2024
|
James R Neal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,920
+42.38%
|
-
|
|
Feb 08
2024
|
Stephanie Diaz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,800
+40.63%
|
-
|
|
Feb 08
2024
|
Robert J. Trenschel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,920
+42.38%
|
-
|
|
Feb 08
2024
|
Cristina Csimma Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,800
+40.47%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 81.7K shares |
|---|---|
| Grant, award, or other acquisition | 666 shares |
| Open market or private purchase | 32K shares |
| Payment of exercise price or tax liability | 5.72K shares |
|---|